Background The recommended spectrophotometric scanning for diagnosis of subarachnoid haemorrhage (SAH) is relatively expensive, not fully automated and often requires expert interpretation. Analysis of cerebrospinal fluid (CSF) bilirubin offers an alternative approach and may obviate the need for scanning and, hence, we undertook a prospective validation study.
Introduction
Subarachnoid haemorrhage (SAH) is spontaneous arterial bleeding into the subarachnoid space, a potentially fatal condition for which prompt diagnosis and treatment has a favourable in£uence on clinical outcome. 1 The majority of cases are detected by computed tomographic (CT) scanning, although this may be normal in up to 5% of patients who are investigated within one or two days after SAH, 2 in which case lumbar puncture is indicated. Following haemorrhage into the cerebrospinal £uid (CSF), red cells lyse releasing oxyhaemoglobin, which is metabolized to bilirubin, for which the detection of elevated levels is the basis for the diagnosis of in vivo haemorrhage. 3 UK guidelines for the detection of CSF bilirubin in suspected SAH have recommended spectrophotometric scanning with net bilirubin absorbance (NBA) calculated according to Chalmers' modi¢cation. 4 , 5 The procedure, however, is not ideally suited for a clinical laboratory environment and requires dedicated, expensive equipment and skilled interpretation. Furthermore, many hospital laboratories in the USA 6 and elsewhere still rely on visual inspection as a means to determine CSF xanthochromia. We reported an alternative approach to diagnosis, based on the measurement of CSF bilirubin on an automated instrument, using the Jendrassik and Gro Ł f method, calibrated to measure lower concentrations. 7 We found that at a CSF bilirubin cut-o¡ of 359 nmol/L, based on our upper reference interval, there was 100% negative predictive value 7 for a NBA greater than 0.007. We propose that this could be used as a screening approach with only those CSF samples with bilirubin values above this cut-o¡ submitted for spectrophotometric scanning. We now report a prospective validation study of automated CSF bilirubin measurement versus spectrophotometric scanning and also clinical outcomes in order to establish a more secure case for this alternative approach.
Patients and methods
All patients from within our region (n ¼ 270) who had requests for 'CSF xanthochromia' from 1 January 2004 to the end of December 2005 were identi¢ed from our laboratory database. Requests from outside our region were excluded from this original cohort because of logistic di⁄culties in accessing clinical records. Of these patients, 193 (71.5%) had both spectrophotometric scans and CSF bilirubin results available for comparison. Of this group, 162 (83.9%) sets of clinical notes could be retrieved for review through the Medical Records Department at Christchurch Hospital. In each case, clinical notes were reviewed for ¢nal diagnosis, timing of the lumbar puncture, evidence of traumatic tap, follow-up investigations where appropriate and any subsequent admissions or evidence to suggest that a diagnosis of SAH had been missed. The death of any patient within New Zealand (NZ) was ascertained by enquiry with the New Zealand Health Information Service (NZHIS) who maintain the NZ death register. Final diagnoses and clinical outcomes were collated with their respective laboratory results.
In each case, the sample of CSF underwent spectrophotometric scan and was interpreted according to published guidelines, 3 with a cut-o¡ value of 40.007 for NBA being de¢ned as positive. In all positive cases, a corrected value (cNBA) was determined using CSF and serum protein, and serum bilirubin. 3 CSF bilirubin was measured by a previously described modi¢cation of our routine serum bilirubin assay, an in-house method on an Aeroset analyser (Abbott Laboratories), as described previously. 7 The method is based on the Jendrasik--Gro Ł f principle as described by Doumas et al., 8 with a modi¢cation of the diazo reagent according to that of Chan et al. 9 Our method employs an adjustment to measure bilirubin at levels normally found in CSF, 7 which involves adjusting the sample to reagent volume ratio from 0.043 to 0.150. The calibrator was also diluted 7 to give a sevenpoint standard curve ranging from 0 to 10550 nmol/L. Intra-assay coe⁄cient of variation is 20% at 100 nmol/ L and 7% at 400 nmol/L. 7 CSF bilirubin was tested for its ability to predict those patients who showed increased NBA (NBA40.007) by spectrophotometry (positive scan) and by corollary, to exclude those patients with negative scans. This was investigated by the receiver operating characteristics (ROC) curve analysis, using the Medcalc software (Medcalc; version 8.1.0.0, www.medcalc.be).
In order to facilitate comparison, the NBA values were transformed into NBA-derived CSF bilirubin in nmol/L units by using the extinction coe⁄cient of 0.000042 M À1 cm
À1
. Regression analysis (x ¼ NBAderived CSF bilirubin; y ¼ CSF bilirubin) was performed, also with the Deming correction (Medcalc; version 8.1.0.0).
This prospective validation study was approved by the Upper South A Regional Ethics Committee (Ministry of Health, 250 Oxford Terrace, PO Box 3877, Christchurch).
Results
This study included 193 cases for which both spectrophotometric scan and CSF bilirubin assay were available. Fourteen cases had uncorrected peak absorbance above 0.007, of which nine cases remained elevated after correction for CSF protein and plasma bilirubin, and were reported as positive. The other cases that corrected to below the cut-o¡ invoked discussion with the attending clinicians that elevated CSF protein or plasma bilirubin could account for the ¢ndings, although SAH could not necessarily be excluded.
Of the nine cases that were reported as positive (elevated cNBA), eight were con¢rmed as having had SAH, by angiography (digital subtraction angiography, CT angiography). Angiographic ¢ndings in the other case were negative for aneurysm or other vascular abnormalities. The patient was managed conservatively with the view that SAH could not be excluded. CSF bilirubin identi¢ed all of these cases with clinically proven SAH, and no positive SAH cases were missed using this assay. Another case had an uncorrected NBA of 0.007, which corrected to 0.0062, and may otherwise have been reported as negative. This case had a CSF bilirubin of 568 nmol/L (above our upper reference limit of 359 nmol/L), and the clinicians were alerted that there was a high probability of SAH, which was con¢rmed on subsequent angiography. None of the above cases had CSF samples taken before 12 h had elapsed from the time of onset of symptoms, and none was a¡ected by traumatic tap at the time of lumbar puncture.
A scattergram (Figure 1) shows the CSF bilirubin levels for those with elevated NBA (40.007) versus those with no elevation (p0.007). For the ability of CSF bilirubin assay to predict elevated NBA, an ROC curve analysis (Figure 2 ) gave an area under the curve of 0.99 (95% con¢dence interval: 0.97--1.00). Statistical parameters (sensitivity, speci¢city, positive and negative predictive values and positive likelihood ratios) corresponding to the di¡erent cut-o¡s are shown in Table 1 , with an optimal cut-o¡ of 380 nmol/L. For prediction of elevated cNBA, after correction for CSF Ann Clin Biochem 2007; 44: 140-144 protein and plasma bilirubin, the optimal cut-o¡ was 695 nmol/L.
From review of the clinical records, 18 (11.1%) of the cases had lumbar punctures done before the recommended 12 h 1 had elapsed from the onset of symptoms. There was evidence of traumatic tap in 24 (14.8%) cases. The ¢nal diagnoses for those with elevated cNBA are shown in Table 2 , with nine cases of con¢rmed or probable SAH (5.5%) and 95 cases were assigned a generic diagnosis of 'benign headache' (58.6%). Two deaths on follow-up were reported from the NZHIS, though from causes unrelated to the initial headache (squamous cell carcinoma of the larynx and ischaemic heart disease). There was no evidence to suggest a missed diagnosis of SAH in any of the cases reviewed.
Even though the clinical outcomes of the remaining 31 cases could not be veri¢ed, they were considered to have a very low probability of SAH, given their levels of CSF bilirubin below 359 nmol/L, absence of elevated NBA and lack of recurrent hospital presentation with SAH or mortality during a median follow-up period of 12 months.
Weighted Deming's regression analysis (x ¼ NBA derived CSF bilirubin; y ¼ CSF bilirubin and assuming 3% error for both methods) gave the following results: y ¼1.04x þ 284, with 95% CIs of 0.79--1.28 for the slope and 252--315 for the intercept. The coe⁄cient of determination (R 2 ) was 0.93 (Po0.001).
Discussion
Our prospective validation con¢rms that CSF bilirubin analysis is a reliable marker for positive cases of xanthochromia, as de¢ned by spectrophotometric scanning. These results indicate that the two methods are comparable, and the use of CSF bilirubin analysis can be considered as an alternative approach or as a screen to identify cases that need to be con¢rmed by spectrophotometry. This may be of value to laboratories where spectrophotometric analysis is unavailable and where they still rely on the inferior method of visual inspection. 6 An added advantage is that small volumes of sample, around 100 mL (compared with 0.5 mL needed for disposable cuvettes for absorbance scans) are su⁄cient for the CSF bilirubin determination.
From ROC curve analysis, the optimal cut-o¡ for prediction of elevated NBAwas 380 nmol/L and for cNBA it was 695 nmol/L, which is much above the upper reference interval of 359 nmol/L. Adoption of this higher optimal cut-o¡, however, would have led to missing one case of con¢rmed SAH with CSF bilirubin of 568 nmol/L. There are broad CIs, however, around the estimates for sensitivity and speci¢city (Table 1) . At 359 nmol/L, there is 100% sensitivity and, by corollary, 100% negative predictive value for prediction of elevated NBA. At this cut-o¡, there is speci¢city of 92.2%, and thus a false-positive rate of 7.8% of cases, which would not have elevated NBA on spectrophotometric scanning. Likelihood ratios are also presented in Table 1 , with a positive likelihood ratio of 12.8 at the cut-o¡ of 359 nmol/L. Likelihood ratios are a derivative of true-positives divided by false-positives --a value of greater than or equal to10 being considered to generate large, often conclusive, changes in post-test probability 10 and values between 5 and 10 resulting in moderate shifts in post-test probability. By corollary, the negative likelihood ratio, the probability of a negative result (CSF bilirubin o359 nmol/L) in a patient with NBA 40.007, compared with a patient with NBAp0.007, was zero (Table 1) .
Interestingly, there was one case with elevated cNBA and CSF bilirubin, though with SAH not con¢rmed on angiography. This case was managed conservatively and with the opinion that SAH could not be excluded. In some series, angiography has been found to be negative in up to 30% patients with SAH.
11
There is further support for our proposed screening approach from the review of clinical records, with no evidence of any case of SAH having been missed. From the data supplied by the NZHIS, there were two deaths in our study cohort, though from causes unrelated to SAH. An analysis of the ¢nal diagnoses (Table 2) shows that over 50% were assigned a generic diagnosis of 'benign headache', and only 5.5% of samples were associated with a diagnosis of SAH.
We thus identi¢ed 10 cases of SAH from our region through our laboratory in a two-year period. The crude annual incidence of SAH in Australasia is 8.1 cases per 100,000. 12 Given that we serve a catchment with a population of 450,000, one would expect there to be 73 cases of SAH in a two-year period, of which 90--95% could be detected on CT scanning, leaving around seven cases needing to be con¢rmed by lumbar puncture. We are, therefore, detecting just above the expected number of cases through the laboratory in this time period. It should be noted that our Radiology Department also installed a new ¢fth-generation CT scanner on 20 June 2005, i.e. part-way during the study period. There is some evidence that newer scanners may be more sensitive for the detection of SAH. 13 Follow-up studies will enable us to investigate this further.
Although most authorities agree that the presence of xanthochromia is the primary biochemical criterion for a diagnosis of SAH, it may be absent especially if the lumbar puncture was done less than 12 h after the event.
1 Our review of the clinical records showed that 89% of lumbar punctures were obtained after the recommended time period of 12 h had elapsed. By corollary, 11% of lumbar punctures were done before 12 h had elapsed from the time of symptoms, indicating scope for education and further audit of clinicians in this area. In 14.7% cases, there was evidence of traumatic tap at the time of lumbar puncture, which can potentially confound the interpretation of whether SAH has occurred or not. An oxyhaemoglobin peak on the spectrophotometric scan could be due to either in-vivo or in-vitro haemorrhage and can potentially a¡ect the baseline for measurement of NBA on scanning. 3 The UK guidelines accommodate this in their recommendations for interpretation, 3 especially if oxyhaemoglobin absorbance is 40.1 absorbance unit, when 'subarachnoid haemorrhage cannot be excluded'. It is still, however, a potentially confounding factor. Measurement of CSF bilirubin may be less susceptible to interference in this situation. Preliminary data also suggest some negative interference of haemoglobin on CSF bilirubin. This requires further study and quantitation, although it also a¡ects NBA derived by spectrophotometry. For operational purposes, we propose that CSF samples should be submitted to spectrophotometry if the analyser haemolytic index is greater than 2.0 mg/ dL --thus consistent with presence of haemoglobin.
Our current results also con¢rm the previously reported bias of CSF bilirubin with respect to bilirubin concentration derived from the absorbance data, with a y intercept of 284 nmol/L compared with 249 in our original report. 7 The reason for the bias is uncertain, although it should be noted that the scanning gives a derivative which itself has not been formally validated as a measure of CSF bilirubin. Many of the spectrophotometric scans were '£at', with approximately 50 of the NBA results being zero. An absorbance of 0.007 at 476 nm corresponds to a bilirubin level of166 nmol/L. The expected normal bilirubin level in CSF is in the order of 30--150 nmol/L, with an expected mean of 90 nmol/L.
14 Around 85% of our original CSF samples tested gave NBA negative results. 7 The mean NBA in this group was 0.001, and corresponded to a bilirubin value of 24 nmol/L, which was lower than expected. A zero CSF bilirubin is unlikely, and the sensitivity of scanning at low levels is probably inadequate. All of these considerations should not in£uence clinical decision limits, however, given the performance data that we have shown previously and in the current validation study.We believe that this methodology should be easily transferable to similar analytical platforms, although it is imperative that each laboratory should meticulously validate its own analytical performance.
In conclusion, the automated bilirubin measurement is an easy and robust test and can be used in a stat environment to screen for patients with elevated NBA as de¢ned by spectrophotometric scanning. The method can easily be performed on automated chemistry analysers, using the onboard serum bilirubin reagent. It may be particularly useful in peripheral laboratories as a screen to identify those samples that need to be con¢rmed by spectrophotometry in a major centre.
